Background: To be sustainable, pharmacists providing direct patient care must receive appropriate payment for these services. This prespecified substudy of the RxACTION trial (a randomized trial of pharmacist prescribing vs usual care in patients with above-target blood pressure [BP]) aimed to determine if BP reduction achieved differed between patients whose pharmacist was paid by pay-for-performance (P4P) vs fee-for-service (FFS).
Methods: Within RxACTION, patients with elevated BP assigned to the pharmacist prescribing group were further randomized to P4P or FFS payment for the pharmacist. In FFS, pharmacists received $150 for the initial visit and $75 for follow-up visits. P4P included FFS payments plus incentives of $125 and $250 for each patient who reached 50% and 100% of the BP target, respectively. The primary outcome was difference in change in systolic BP between P4P and FFS groups.
Results: A total of 89 patients were randomized to P4P and 92 to the FFS group. Patients' average (SD) age was 63.0 (13.2) years, 49% were male and 76% were on antihypertensive drug therapy at baseline, taking a median of 2 (interquartile range = 1) medications. Mean systolic BP reductions in the P4P and FFS groups were 19.7 (SD = 18.4) vs 17.0 (SD = 16.4) mmHg, respectively (p = 0.47 for the comparison of deltas and p = 0.29 after multivariate adjustment).
Conclusions: This trial of pharmacist prescribing found substantial reductions in systolic BP among poorly controlled hypertensive individuals but with no appreciable difference when pharmacists were paid by P4P vs FFS.
Conflict of interest statement
Declaration of Conflicting Interests:The authors declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.
Pharmacists' perceptions of pay for performance versus fee-for-service remuneration for the management of hypertension through pharmacist prescribing.Int J Pharm Pract. 2017 Oct;25(5):388-393. doi: 10.1111/ijpp.12330. Epub 2017 Jan 18. Int J Pharm Pract. 2017. PMID: 28097711
Randomized Trial of the Effect of Pharmacist Prescribing on Improving Blood Pressure in the Community: The Alberta Clinical Trial in Optimizing Hypertension (RxACTION).Circulation. 2015 Jul 14;132(2):93-100. doi: 10.1161/CIRCULATIONAHA.115.015464. Epub 2015 Jun 10. Circulation. 2015. PMID: 26063762 Clinical Trial.
Effectiveness of home blood pressure monitoring, Web communication, and pharmacist care on hypertension control: a randomized controlled trial.JAMA. 2008 Jun 25;299(24):2857-67. doi: 10.1001/jama.299.24.2857. JAMA. 2008. PMID: 18577730 Free PMC article. Clinical Trial.
Improving hypertension management through pharmacist prescribing; the rural Alberta clinical trial in optimizing hypertension (Rural RxACTION): trial design and methods.Implement Sci. 2011 Aug 11;6:94. doi: 10.1186/1748-5908-6-94. Implement Sci. 2011. PMID: 21834970 Free PMC article. Clinical Trial.
Effect of home blood pressure telemonitoring and pharmacist management on blood pressure control: a cluster randomized clinical trial.JAMA. 2013 Jul 3;310(1):46-56. doi: 10.1001/jama.2013.6549. JAMA. 2013. PMID: 23821088 Free PMC article. Clinical Trial.
Cited by 3 articles
Major concerns remain around pay-for-performance programs in Canada.Can Pharm J (Ott). 2018 Dec 17;152(1):54-55. doi: 10.1177/1715163518816666. eCollection 2019 Jan-Feb. Can Pharm J (Ott). 2018. PMID: 30719198 Free PMC article. No abstract available.
Pharmacist services for non-hospitalised patients.Cochrane Database Syst Rev. 2018 Sep 4;9(9):CD013102. doi: 10.1002/14651858.CD013102. Cochrane Database Syst Rev. 2018. PMID: 30178872 Free PMC article. Review.
A scoping review of research on the prescribing practice of Canadian pharmacists.Can Pharm J (Ott). 2015 Nov;148(6):325-48. doi: 10.1177/1715163515608399. Can Pharm J (Ott). 2015. PMID: 26600824 Free PMC article. Review.